




The relative strengths and weaknesses of Generex Biotechnology CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Generex Biotechnology CORP compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Generex Biotechnology CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 129%, being 127% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	1,255
Cost of Goods Sold	0
Intangible Assets	43,855
Liabilities, Current	41,371
Liabilities, Non-Current	0
Other Assets	60
Other Compr. Net Income	0
Other Expenses	12,587
Other Liabilities	11,896
Other Net Income	-1,640
Other Revenues	0
Property and Equipment	214
Research and Development	2,106
Selling, General and Administrative Expense	17,898

Output Variable	Value in 1000 USD
Assets	45,383
Liabilities	53,267
Expenses	32,592
Revenues	0
Stockholders Equity	-7,884
Net Income	-34,232
Comprehensive Net Income	-34,232
BaseVar	66,441
ECR before LimitedLiability	-104%
Economic Capital Ratio	129%